Oragenics Inc. - רווח למניה אחת ב-12 החודשים האחרונים OGEN

סמלים רשמיים של חברת oragenics.com (OGEN)

Oragenics, Inc. (OGEN) minimizes investment risks by creating a diversified portfolio of nasal infection treatments. The TTM net income per share annual trend visualizes these changes, where the 87.70 level indicates the status of the yield parameter. Antibiotic development relies on partnerships with the public sector, while the environmental profile is based on strict compliance with chemical handling standards.

Oragenics, Inc. (OGEN): רווח נקי למניה (EPS TTM) מ-11.02.2024 עד 17.11.2026

Oragenics Inc. - פילוחים אנליטיים ומדדי מפתח (OGEN)

- מחיר מניה וקונצנזוס הערכת שווי:
- פרטי שווי השוק של המנפיק:
ניתוח ראשוני של החברה:OGEN, Oragenics Inc.
מוצרים מיוצרים של Oragenics

This metric measures the rate of change in net earnings per share over the last twelve months. By analyzing the annual EPS TTM delta, an investor assesses profit generation efficiency relative to the previous year. The metric is calculated as the percentage deviation of the current rolling earnings value from the same period. For Oragenics, Inc. (OGEN), this trend reflects the monetization of a closed biopharmaceutical patent perimeter. Growth in this indicator confirms the commercial success of exclusively supplying medical centers with innovative proteins.